Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Children With Fibrous Dysplasia
NCT05419050Phase 2Completed
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Oct 2022
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in fibrous dysplasia, sponsored by National Institute of Dental and Craniofacial Research. Started Oct 2022; status: completed.
02
Drugs
denosumab
03
Conditions
fibrous dysplasia
Beyond the preview
Go deeper on NCT05419050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419050.